SastaSundar to pump Rs 130cr, aims to break even in 2017-18

Published On 2015-12-01 05:38 GMT   |   Update On 2015-12-01 05:38 GMT
Advertisement
Kolkata : Online pharmacy major SastaSundar, a subsidiary of public-traded Microsec Financial Services Ltd, is planning to invest Rs 130 crore to expand its operation and is aiming to break even in 2017-18.

"We have already turned into the largest online pharmacy servicing about 3,000 orders per day. We hope to break even in 2017-18", SastaSundar Chairman B L Mittal said today.

He also said the company was planning to invest Rs 130 crore over the next one year to expand its footprint in Maharashtra and Bengaluru.
Advertisement

The online pharmacy is servicing only in six districts of West Bengal as regulation restricts pharmacies to ship medicines out of the state unless the company has obtained drug license in the state where the drugs are supplied, Mittal said.

SastaSundar CEO Ravi Kant Sharma said the company had so far infused Rs 110 crore including manufacturing facility for FMCG products.

He said the company was moving towards bringing innovation in creating infrastructure to offer products and services tailored to an individual.

In a step toward this, the company has introduced Dnavita, first in the history of health supplement industry, Sharma said.

He said based on individual's health condition and nutrition requirement, Dnavita will be tailored and delivered to the customer.

"A customer has to provide details and interactions with the in house nutritionists, the health supplement will be customised and delivered in 3 days of order", Sharma said. BSM MD ANU
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News